AATB Accreditation, Federal Compliance, and the State-by-State Legal Landscape for Stem Cell Biologics in 2026
As the regenerative biologics market grows, licensed practitioners are asking two questions more frequently than ever: what does AATB accreditation actually mean, and what does the law say in my state about stem cell biologics? This guide answers both — covering the federal regulatory baseline, what AATB accreditation requires and why it matters for sourcing decisions, compliant vs. non-compliant marketing language, and the current legislative landscape across the states most active in this space as of early 2026.
This is a regulatory reference for licensed practitioners. It does not constitute legal advice. Practitioners should consult qualified legal counsel for guidance specific to their practice, jurisdiction, and the products they are sourcing or using.
Part 1: The Federal Regulatory Baseline
21 CFR Part 1271 — The HCT/P Framework
At the federal level, human cell, tissue, and cellular and tissue-based products (HCT/Ps) — including umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs) and exosome biologics — are regulated under 21 CFR Part 1271. This framework governs how these products are manufactured, tested, stored, and distributed.
Under the Section 361 pathway, certain HCT/Ps may be exempt from premarket FDA approval if they are minimally manipulated, intended for homologous use, not combined with a drug or device, and do not have a systemic effect dependent on the metabolic activity of living cells. Products that do not meet all of these criteria require premarket review — including an Investigational New Drug (IND) application or Biologics License Application (BLA).
What Federal Law Requires from Manufacturers
- ✓FDA establishment registration — tissue establishments must be registered with the FDA as HCT/P manufacturers
- ✓Current Good Tissue Practice (cGTP) — manufacturing must comply with cGTP standards under 21 CFR Part 1271 (not cGMP, which applies to pharmaceutical drugs)
- ✓Donor eligibility determination — full donor screening including infectious disease testing per 21 CFR Part 1271 Subpart C
- ✓Lot-specific testing and traceability — sterility, endotoxin, mycoplasma, and identity markers documented per lot
- ✓Adverse event reporting — manufacturers must report adverse reactions potentially related to their HCT/P products
Part 2: What AATB Accreditation Means
What AATB Is
The American Association of Tissue Banks (AATB) is a nonprofit professional organization that establishes voluntary accreditation standards for tissue banks and tissue establishments. AATB has developed comprehensive standards for donor screening, tissue processing, packaging, labeling, storage, and distribution that go beyond the minimum FDA regulatory requirements.
AATB accreditation is not a government certification — it is a rigorous voluntary quality standard that requires a facility to undergo regular independent inspection and demonstrate compliance with AATB's published standards across every aspect of its operations.
What the Accreditation Process Requires
- ✓Donor screening and eligibility — comprehensive review of donor medical history, social behavior history, physical assessment, and relevant lab testing
- ✓Infectious disease testing — mandatory testing for a defined panel of communicable disease agents per AATB standards
- ✓Processing and manufacturing controls — validated SOPs, environmental monitoring, equipment qualification, and process controls
- ✓Quality management system — documented QMS including deviation management, CAPA processes, and change control
- ✓Storage and distribution — validated cold-chain procedures, shipping qualification, and chain of custody documentation
- ✓Inspection and ongoing surveillance — facilities must pass AATB on-site inspections and maintain compliance to retain accreditation
Part 3: Compliant vs. Non-Compliant Marketing Language
Even in states with active stem cell legislation, the language practitioners use to describe these products to patients and in marketing materials is heavily scrutinized by the FDA and FTC. The following guidance applies regardless of which state you practice in.
Exosome Biologics — Topical Cosmetic Use Only
❌ Never Use
- Treats inflammation / anti-inflammatory
- Regenerates tissue / promotes healing
- Activates stem cells
- Injectable-grade
- FDA compliant / FDA approved
- Proven to improve [condition]
- Repairs / restores / reverses
- Any disease name (arthritis, hair loss, wound healing, neuropathy)
- Better outcomes / superior results
✅ Compliant Language
- For topical cosmetic use only
- Not for injection or therapeutic use
- Not FDA-approved
- Biological signaling profile
- Cellular uptake characteristics
- Post-procedure topical support
- Visible radiance / the look of skin texture
- NTA-verified particle count
- For use by licensed professionals only
UCT-MSC Stem Cells — For States with Active Legislation
❌ Never Use
- FDA approved / FDA legal in this state
- Proven to treat [condition]
- Cures / heals / reverses disease
- Better outcomes than standard care
- Legal alternative to surgery
- Disease names in promotional materials
- Safe and effective (implies FDA approval)
✅ Compliant Language
- Performed by a licensed physician subject to applicable state and federal requirements
- Not approved by the U.S. Food and Drug Administration
- Patients should consult their primary care provider
- For physician evaluation only
- Investigational — individual results may vary
- Sourced from AATB-accredited, FDA-registered tissue establishment
- cGTP-compliant per 21 CFR Part 1271
Part 4: State-by-State Legal Landscape
Several states have enacted legislation creating pathways for licensed physicians to use non-FDA-approved stem cell biologics under defined conditions. This section covers all active, disclosure-only, and pending states as of early March 2026. State laws govern the practice of medicine within a state — they do not override FDA's authority over the products themselves.
Florida's SB 1768 (codified as Florida Statute § 458.3245) is the most significant and well-structured state stem cell law in the country. It authorizes licensed MDs and DOs to perform non-FDA-approved stem cell therapy under clearly defined conditions.
- Who can administer: Licensed physicians only — MDs (Chapter 458) and DOs (Chapter 459)
- Covered indications: Orthopedics, wound care, and pain management only
- Cell sources permitted: Adult-derived stem cells from human tissue including birth tissue. Embryonic, fetal, and adipose-derived tissue explicitly excluded.
- Supplier requirements: Products must come from FDA-registered facilities accredited by AATB or other listed organizations. Manufacturing must comply with 21 CFR Part 1271.
- Required advertising notice: All advertising must include a statutory disclosure that the physician performs stem cell therapies not yet approved by the FDA.
- Exosomes: Not explicitly covered. Practitioners should consult legal counsel before administering exosome biologics under SB 1768.
SNN relevance: Stem Nova Network's supplier is AATB-accredited, FDA-registered, and cGTP-compliant per 21 CFR Part 1271 — meeting SB 1768's sourcing requirements for covered stem cell products.
Texas was one of the first states to create a legislative pathway for investigational stem cell therapy, building on its Right to Try framework. HB 810 extended Right to Try access — originally for terminal patients — to patients with severe chronic illness for adult stem cell biologics specifically.
- Right to Try connection: Texas passed its state Right to Try law in 2015 for terminal patients. HB 810 extended that framework to patients with severe chronic illness for adult stem cell biologics — a separate, stem-cell-specific access pathway.
- Who can administer: Licensed physicians at a hospital, medical school, or registered outpatient facility (outpatient added by HB 5147) with IRB oversight
- Eligible patients: Patients with severe chronic disease or terminal illness
- Clinical trial requirement: The stem cell treatment must have been tested on humans in a clinical trial (not required to be a U.S. trial)
- 2025 update (HB 5147): Expanded to outpatient settings with physician registration. IRBs now submit annual adverse event reports to the Texas Medical Board.
Utah's SB 199 is the broadest state stem cell access law currently in effect, allowing administration of placental and perinatal stem cell therapies by a wide range of licensed providers with patient disclosure — but without the supplier quality standards Florida requires.
- Who can administer: Any licensed healthcare provider whose scope includes stem cell therapy — physicians, naturopaths, chiropractors, nurses, midwives
- Requirements: Disclosure to patients and signed informed consent. No clinical trial requirement. No mandatory supplier accreditation standards.
- Federal conflict: Utah SB 199 explicitly permits therapies the FDA considers to require premarket approval. Practitioners should consult legal counsel before relying on this law.
California's SB 512 is a consumer protection and disclosure law — not a treatment authorization. California's Medical Board has actively warned practitioners against administering unapproved stem cell products. The only legal path for exosome or stem cell therapy use in California is within a formal FDA-approved IND clinical trial.
- Required notice (exact statutory language): "THIS NOTICE MUST BE PROVIDED TO YOU UNDER CALIFORNIA LAW. This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care physician prior to undergoing a stem cell therapy."
- Where it must appear: Posted prominently at office entrance, in patient-visible areas, included in all advertising, and provided in writing to the patient before initial treatment
- Enforcement: $1,000 fine per violation after the first violation
- Practical guidance: California is not a treatment-authorization state. SB 512 governs how practitioners must communicate — it does not create a green light for administering unapproved products.
Nevada has two separate pieces of legislation relevant to regenerative biologics, representing one of the more permissive state environments — though with significant federal conflict concerns.
- 2023 biologics law: Allows licensed providers to offer non-FDA-approved biologics including allogeneic cellular material as "individualized investigational treatments." Broad language with no IRB or clinical trial requirement. Creates significant state-federal enforcement tension — practitioners should consult legal counsel before relying on this law.
- SB 128 — effective January 1, 2026: A provider disclosure law requiring licensed physicians, PAs, APRNs, and DOs to discuss stem cell therapy options with patients diagnosed with conditions like arthritis. This is a discussion mandate — not a treatment authorization.
Vermont's Act 61 is a consumer protection and informed consent law — not a treatment authorization. Practitioners administering non-FDA-approved stem cell products in Vermont must post required notices at the office entrance and in patient-visible areas, include the notice in all advertising, and obtain a signed disclosure form from patients before each administration. A copy must be retained in the medical record.
Montana (SB 535) and New Hampshire (HB 1292) have expanded their Right to Try frameworks to include experimental regenerative therapies. Montana's expansion covers experimental autologous treatments that have passed Phase I safety trials. New Hampshire permits access to certain regenerative therapies under a state-level medical freedom framework. Both apply primarily to patients seeking access to experimental therapies, not to commercial allogeneic supplier relationships.
Mississippi and North Carolina have each passed Stem Cell Intervention (SCI) laws allowing licensed physicians to use investigational stem cell therapies for patients with severe chronic or terminal illness, under physician oversight and with informed consent. Structured similarly to the original Texas HB 810 framework, these laws typically require the intervention to have some basis in human clinical trial data.
Arizona's SB 1214 cleared the Senate Health & Human Services Committee in February 2026 and is heading to the full Senate floor. It is not yet law but is the most significant pending stem cell legislation in the country as of this writing.
- Modeled after Florida SB 1768: Authorizes licensed MDs and DOs to perform non-FDA-approved stem cell and birth tissue therapies for orthopedics, wound care, and pain management
- Supplier requirements: Products must come from FDA-registered facilities accredited by AATB, AABB, or similar organizations — explicitly naming AATB
- Informed consent: Required with full disclosure of non-approval status, risks, benefits, and alternatives
- Fetal tissue prohibition: Cells from aborted fetuses or embryos explicitly banned — willful violations classified as a Class 5 felony
- Civil remedies: Patients harmed by violations may seek $10,000 per violation plus attorney fees
- Status: Passed committee February 19, 2026. Moving to full Senate floor vote.
This legislation is not yet law. Verify current status and consult legal counsel before making any clinical or sourcing decisions in reliance on its provisions.
Part 5: Complete State Comparison
Updated March 2026. Not legal advice — verify current law with qualified counsel before making clinical or sourcing decisions.
| State | Law | Status | Type | AATB Required |
|---|---|---|---|---|
| Florida | SB 1768 | Active July 2025 | Treatment authorization | Yes — explicitly named |
| Texas | HB 810 + HB 5147 | Active / Updated 2025 | Right to Try + investigational | IRB oversight required |
| Utah | SB 199 | Active May 2024 | Permissive / disclosure | Not specified |
| California | SB 512 | Active | Disclosure only — not treatment auth | N/A |
| Nevada | 2023 law + SB 128 | Active / Updated Jan 2026 | Biologics access + disclosure | Not specified |
| Vermont | Act 61 | Active | Disclosure only — not treatment auth | N/A |
| Montana | SB 535 | Active | Right to Try expansion | Not specified |
| New Hampshire | HB 1292 | Active | Medical freedom framework | Not specified |
| Mississippi | SCI law | Active | Physician-supervised access | Not specified |
| North Carolina | SCI law | Active | Physician-supervised access | Not specified |
| Arizona | SB 1214 | Pending — Senate floor | Treatment authorization (if passed) | Yes — if passed |
Request Full Supplier Documentation
AATB accreditation confirmation, FDA registration, lot-specific CoAs, and full cGTP compliance documentation — available to licensed professionals upon credential verification.
Contact Our Team